Militia Capital Management LLC Makes New $863,000 Investment in PROCEPT BioRobotics Corporation $PRCT

Militia Capital Management LLC purchased a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 34,500 shares of the company’s stock, valued at approximately $863,000. Militia Capital Management LLC owned 0.06% of PROCEPT BioRobotics at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. AQR Capital Management LLC grew its holdings in PROCEPT BioRobotics by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock worth $1,101,000 after buying an additional 1,286 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in PROCEPT BioRobotics by 9.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock valued at $8,923,000 after acquiring an additional 13,767 shares during the period. Intech Investment Management LLC raised its stake in PROCEPT BioRobotics by 54.4% during the 1st quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock valued at $1,654,000 after acquiring an additional 10,002 shares in the last quarter. Prudential Financial Inc. raised its stake in PROCEPT BioRobotics by 100.4% during the 2nd quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock valued at $393,000 after acquiring an additional 3,415 shares in the last quarter. Finally, State Street Corp boosted its position in PROCEPT BioRobotics by 6.9% during the 2nd quarter. State Street Corp now owns 1,269,110 shares of the company’s stock worth $73,101,000 after acquiring an additional 81,849 shares during the period. Institutional investors own 89.46% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Evercore began coverage on shares of PROCEPT BioRobotics in a report on Wednesday, June 24th. They issued an “outperform” rating and a $30.00 price objective for the company. Leerink Partners lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $31.00 to $29.00 in a research report on Thursday, June 11th. Finally, Truist Financial reissued a “hold” rating and set a $25.00 target price (down from $30.00) on shares of PROCEPT BioRobotics in a research note on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $37.27.

PROCEPT BioRobotics Trading Down 0.8%

Shares of PROCEPT BioRobotics stock opened at $17.55 on Friday. The company has a quick ratio of 5.51, a current ratio of 6.73 and a debt-to-equity ratio of 0.15. The firm has a market cap of $998.95 million, a price-to-earnings ratio of -9.64 and a beta of 0.87. The business has a fifty day simple moving average of $23.53 and a 200-day simple moving average of $25.81. PROCEPT BioRobotics Corporation has a fifty-two week low of $17.17 and a fifty-two week high of $60.57.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01). The firm had revenue of $83.13 million for the quarter, compared to the consensus estimate of $80.52 million. PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The company’s quarterly revenue was up 20.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.45) EPS. On average, equities analysts forecast that PROCEPT BioRobotics Corporation will post -1.53 EPS for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.